Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 523

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 523
---
.

On November 1, 2024, December 2, 2024, and January 7, 2025, the Company funded additional advances under the Amended Note, as discussed in Note 7 to these unaudited condensed financial statements, of $0.8 million.

<div align='center'>F-68</div>

TABLE OF CONTENTS

#### LIMINATUS PHARMA, LLC

### NOTES TO CONDENSED FINANCIAL STATEMENTS

#### SEPTEMBER 30, 2024
<div align='center'>**(Unaudited)**</div>

On December 26, 2024, the Company entered into a seventh amendment to the Business Combination Agreement extending the outside date to June 30, 2025.

On December 26, 2024, Iris, Iris Parent Holding Corp. and the Company entered into a sixth amendment to the equity subscription agreement with Ewon extending the deadline for which the subscriber can terminate the agreement to June 30, 2025.

On January 2, 2025, the Company borrowed $0.3 million from Amantes, a related party of the Company due to having common executives, pursuant to a Loan Agreement between the Company and Amantes (the “2025 Amantes Loan”). The Amantes Loan bears interest at 6% per annum and is due on March 1, 2025, which may be extended upon mutual agreement of the parties.

<div align='center'>F-69</div>

TABLE OF CONTENTS

### REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors, Stockholders, and Members of Liminatus Pharma, LLC:

### Opinion on the Financial Statements
We have audited the accompanying balance sheets of Liminatus Pharma, LLC (the “Company”) as of December 31, 2023 and 2022, the related statements of operations, changes in members’ deficit and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

The Company